bdtx-20220630
FALSEQ22022000170154112-31http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrentP5YP3YP5Y00017015412022-01-012022-06-3000017015412022-07-28xbrli:shares00017015412022-06-30iso4217:USD00017015412021-12-31iso4217:USDxbrli:shares00017015412022-04-012022-06-3000017015412021-04-012021-06-3000017015412021-01-012021-06-3000017015412020-12-3100017015412021-06-300001701541us-gaap:CommonStockMember2020-12-310001701541us-gaap:AdditionalPaidInCapitalMember2020-12-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001701541us-gaap:RetainedEarningsMember2020-12-310001701541us-gaap:CommonStockMember2021-01-012021-03-310001701541us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100017015412021-01-012021-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001701541us-gaap:RetainedEarningsMember2021-01-012021-03-310001701541us-gaap:CommonStockMember2021-03-310001701541us-gaap:AdditionalPaidInCapitalMember2021-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001701541us-gaap:RetainedEarningsMember2021-03-3100017015412021-03-310001701541us-gaap:CommonStockMember2021-04-012021-06-300001701541us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001701541us-gaap:RetainedEarningsMember2021-04-012021-06-300001701541us-gaap:CommonStockMember2021-06-300001701541us-gaap:AdditionalPaidInCapitalMember2021-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001701541us-gaap:RetainedEarningsMember2021-06-300001701541us-gaap:CommonStockMember2021-12-310001701541us-gaap:AdditionalPaidInCapitalMember2021-12-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001701541us-gaap:RetainedEarningsMember2021-12-310001701541us-gaap:CommonStockMember2022-01-012022-03-310001701541us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100017015412022-01-012022-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001701541us-gaap:RetainedEarningsMember2022-01-012022-03-310001701541us-gaap:CommonStockMember2022-03-310001701541us-gaap:AdditionalPaidInCapitalMember2022-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001701541us-gaap:RetainedEarningsMember2022-03-3100017015412022-03-310001701541us-gaap:CommonStockMember2022-04-012022-06-300001701541us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001701541us-gaap:RetainedEarningsMember2022-04-012022-06-300001701541us-gaap:CommonStockMember2022-06-300001701541us-gaap:AdditionalPaidInCapitalMember2022-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001701541us-gaap:RetainedEarningsMember2022-06-300001701541srt:MaximumMemberbdtx:OpenMarketSaleMembersrt:ScenarioForecastMember2022-07-012022-09-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-06-300001701541us-gaap:CorporateBondSecuritiesMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-06-300001701541us-gaap:CorporateBondSecuritiesMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-3100017015412021-01-012021-12-310001701541us-gaap:EquipmentMember2022-06-300001701541us-gaap:EquipmentMember2021-12-310001701541us-gaap:FurnitureAndFixturesMember2022-06-300001701541us-gaap:FurnitureAndFixturesMember2021-12-310001701541us-gaap:OfficeEquipmentMember2022-06-300001701541us-gaap:OfficeEquipmentMember2021-12-310001701541us-gaap:LeaseholdImprovementsMember2022-06-300001701541us-gaap:LeaseholdImprovementsMember2021-12-310001701541us-gaap:ConstructionInProgressMember2022-06-300001701541us-gaap:ConstructionInProgressMember2021-12-310001701541bdtx:A2020StockOptionPlanMember2020-01-14xbrli:pure0001701541bdtx:A2020StockOptionPlanMember2022-01-012022-01-010001701541bdtx:A2020StockOptionPlanMember2022-01-010001701541bdtx:A2020EmployeeStockPurchasePlanMember2020-01-140001701541bdtx:A2020EmployeeStockPurchasePlanMember2022-01-012022-01-010001701541us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001701541us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001701541us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001701541us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001701541bdtx:OtherAwardTypeMember2022-04-012022-06-300001701541bdtx:OtherAwardTypeMember2021-04-012021-06-300001701541bdtx:OtherAwardTypeMember2022-01-012022-06-300001701541bdtx:OtherAwardTypeMember2021-01-012021-06-300001701541us-gaap:EmployeeStockOptionMemberbdtx:A2020StockOptionPlanMember2022-01-012022-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001701541us-gaap:RestrictedStockMember2021-12-310001701541us-gaap:RestrictedStockMember2022-01-012022-06-300001701541us-gaap:RestrictedStockMember2022-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2022-06-300001701541bdtx:PerformanceRestrictedStockUnitsMember2022-01-012022-06-300001701541bdtx:PerformanceRestrictedStockUnitsMember2022-06-300001701541bdtx:A2020EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2022-01-012022-06-300001701541bdtx:A2020EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2022-06-300001701541bdtx:A2020EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2021-01-012021-06-300001701541us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001701541us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001701541us-gaap:RestrictedStockMember2022-01-012022-06-300001701541us-gaap:RestrictedStockMember2021-01-012021-06-300001701541us-gaap:EmployeeStockMember2022-01-012022-06-300001701541us-gaap:EmployeeStockMember2021-01-012021-06-300001701541us-gaap:WarrantMember2022-01-012022-06-300001701541us-gaap:WarrantMember2021-01-012021-06-30bdtx:contract0001701541bdtx:OperatingLeasePrincipalOfficeTwoMember2020-07-31utr:sqft0001701541bdtx:OperatingLeasePrincipalOfficeOneMember2019-02-2800017015412021-06-152021-06-150001701541bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember2020-12-31
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________________________
FORM 10-Q
_______________________________________________________________________________
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED June 30, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _ TO _
COMMISSION FILE NUMBER 001-38501
___________________________________________
BLACK DIAMOND THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________________________________________________________________
Delaware81-4254660
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification No.)
One Main Street, 14th Floor
Cambridge, Massachusetts
(Address of principal executive offices)
02142
(Zip Code)
(617) 252-0848
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001BDTXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer




Non-accelerated filerSmaller reporting company






Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of July 28, 2022, the registrant had 36,339,466 shares of common stock, $0.0001 par value per share, outstanding.



Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “Quarterly Report”), contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:
the progress, timing and success of preclinical studies and our clinical trials of BDTX-1535, BDTX-4933 and any other product candidates, including the availability, timing and announcement of data and results of such studies and trials;
the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug, or IND, applications and other regulatory submissions;
the continued development and advancement of our FGFR program and the timing for nominating a development candidate;
our ability to obtain and maintain regulatory approval for BDTX-1535 and BDTX-4933 or any of our other current or future product candidates that we may identify or develop;
our need to raise additional funding before we can expect to generate any revenues from product sales;
our ability to identify future product candidates for treatment of additional disease indications;
our ability to develop our current product candidates for the treatment of various cancers;
the rate and degree of market acceptance and clinical utility for any current or future product candidates we may develop;
the effects of competition with respect to BDTX-1535, BDTX-4933 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;
the implementation of our strategic plans for our business, any product candidates we may develop and our Mutation-Allostery-Pharmacology (“MAP”) drug discovery engine;
our ability to successfully develop companion diagnostics for use with our current or future product candidates;
our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates and MAP drug discovery engine;
our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved, and to further expand our MAP drug discovery engine;
the period over which we expect our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements;
the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
our financial performance and our ability to effectively manage our anticipated growth;
our estimates regarding the market opportunities for our product candidates, including our competitive position and the success of competing therapies that are or may become available;
2

Table of Contents
our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire and retain additional qualified professionals;
our ability to establish or maintain collaborations or strategic relationships and the ability and willingness of our third-party strategic collaborators to undertake research and development activities relating to our current or future product candidates;
our expectations regarding the period during which we will remain an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”);
our ability to maintain an effective system of internal controls; and
the ultimate impact of the ongoing coronavirus, or COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole.
Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, “Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K for the year ended December 31, 2021 (the “Annual Report”) and in other Securities and Exchange Commission (the “SEC”) filings. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic, including as a result of the emergence of new variants, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.
This Quarterly Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to this Quarterly Report. In this Quarterly Report, the terms “Black Diamond Therapeutics,” “Black Diamond,” the “Company,” “we,” “us,” “our,” and similar designations refer to Black Diamond Therapeutics, Inc. and, where appropriate, our subsidiaries.

3

Table of Contents
We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.
4

Table of Contents
TABLE OF CONTENTS

Page
PART I - FINANCIAL INFORMATION
PART II - OTHER INFORMATION

We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.
From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.


Table of Contents
Part I - FINANCIAL INFORMATION
Item I. Condensed Consolidated Financial Statements (Unaudited)
Black Diamond Therapeutics, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)

As of

June 30,
2022
December 31,
2021
Assets



Current assets:



Cash and cash equivalents$55,877 

$65,799 
Investments105,013 143,987 
Prepaid expenses and other current assets7,668 

5,917 
Total current assets168,558 

215,703 
Property and equipment, net2,873 

3,035 
Restricted cash1,168 

1,223 
Right-of-use assets26,225 27,705 
Other non-current assets10 

16 
Total assets$198,834 

$247,682 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$2,222 

$4,107 
Accrued expenses and other current liabilities17,484 

19,535 
Total current liabilities19,706 

23,642 
Non-current operating lease liabilities26,757 28,140 
Total liabilities46,463 

51,782 
Commitments and contingencies (Note 10) 

 
Stockholders' equity:

Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued or outstanding at June 30, 2022 and December 31, 2021
  
Common stock; $0.0001 par value; 500,000,000 shares authorized at June 30, 2022 and December 31, 2021; 36,315,737 shares issued and outstanding at June 30, 2022 and 36,234,624 shares issued and outstanding at December 31, 2021
5 

5 
Additional paid-in capital446,909 

440,129 
Accumulated other comprehensive loss(2,286)(414)
Accumulated deficit(292,257)

(243,820)
Total stockholders' equity152,371 

195,900 
Total liabilities and stockholders' equity$198,834 

$247,682 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

Table of Contents
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)

Three Months Ended
June 30,
Six Months Ended
June 30,

2022202120222021
Operating expenses:
Research and development$16,195 $26,719 $33,981 $49,539 
General and administrative6,978 7,996 14,871 15,889 
Total operating expenses23,173 34,715 48,852 65,428 
Loss from operations(23,173)(34,715)(48,852)(65,428)
Other income (expense):
Interest income386 948 792 2,100 
Other (expense) income(143)(584)(377)(1,324)
Total other income (expense), net243 364 415 776 
Net loss$(22,930)$(34,351)$(48,437)$(64,652)
Net loss per share, basic and diluted$(0.63)$(0.95)$(1.33)$(1.79)
Weighted average common shares outstanding, basic and diluted36,293,856 36,182,541 36,282,636 36,152,942 
Comprehensive loss:
Net loss$(22,930)$(34,351)$(48,437)$(64,652)
Other comprehensive income:
Change in unrealized loss on investments(511)(124)(1,872)(403)
Comprehensive loss$(23,441)$(34,475)$(50,309)$(65,055)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7

Table of Contents
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
Six Months Ended
June 30,
2022

2021
Cash flows from operating activities:



Net loss$(48,437)$(64,652)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense6,627 7,652 
Depreciation expense253 39 
Amortization of premium on investments365 1,326 
Noncash rent expense1,371 748 
Other non-cash items (14)
Loss on disposal of property and equipment3  
Changes in current assets and liabilities:
Prepaid expenses and other current assets(1,751)(2,956)
Other non-current assets6 8 
Accounts payable(1,885)1,635 
Accrued expenses and other current liabilities(1,836)7,355 
Non-current operating lease liabilities(1,383)(761)
Net cash used in operating activities(46,667)(49,620)
Cash flows from investing activities:
Purchases of equipment(200)(888)
Proceeds from sales and maturities of investments57,241 95,138 
Purchases of investments(20,504)(42,576)
Net cash provided by investing activities36,537 51,674 
Cash flows from financing activities:
Proceeds from exercise of common stock options and ESPP153 665 
Net cash provided by financing activities153 665 
Net (decrease) increase in cash and cash equivalents(9,977)2,719 
Cash, cash equivalents and restricted cash, beginning of period67,022 35,828 
Cash, cash equivalents and restricted cash, end of period$57,045 $38,547 
Cash and cash equivalents, end of period$55,877 $37,324 
Restricted cash, end of period1,168 1,223 
Cash, cash equivalents and restricted cash, end of period$57,045 $38,547 
Supplemental disclosure of non-cash investing and financing activities:
Purchases of equipment included in accounts payable and accrued expenses $ $1,199 
Right-of-use assets obtained in exchange for operating lease obligation $109 $5,717 
Right-of-use asset derecognized upon early lease termination$ $476 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8

Table of Contents
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders' Equity (Unaudited)
(in thousands, except share data)

Common stock

Additional
paid-in capital

Accumulated other comprehensive income (loss)Accumulated deficit

Total
stockholders’
equity (deficit)

Shares

Par Value



BALANCE - December 31, 202036,078,383 $5 $425,363 $614 $(118,224)$307,758 
Exercise of common stock options62,607 — 481 — — 481 
Vesting of restricted stock units4,998 — — — — — 
Stock-based compensation1,224 — 3,094 — — 3,094 
Unrealized loss on investments— — — (279)— (279)
Net loss— — — — (30,301)(30,301)
BALANCE - March 31, 202136,147,212 $5 $428,938 $335 $(148,525)$280,753 
Exercise of common stock options48,014 — 184 — — 184 
Vesting of restricted stock units8,331 — — — — — 
Stock-based compensation2,269 — 4,558 — — 4,558 
Unrealized loss on investments— — — (124)— (124)
Net loss— — — — (34,351)(34,351)
BALANCE - June 30, 202136,205,826 $5 $433,680 $211 $(182,876)$251,020 
BALANCE - December 31, 202136,234,624 $5 $440,129 $(414)$(243,820)$195,900 
Exercise of common stock options3,565 — 11 — — 11 
Vesting of restricted stock units5,000 — — — — — 
Issuance of common stock related to ESPP31,341 — 142 — — 142 
Stock-based compensation13,038 — 3,375 — — 3,375 
Unrealized loss on investments— — — (1,361)— (1,361)
Net loss— — — — (25,507)(25,507)
BALANCE - March 31, 202236,287,568 $5 $443,657 $(1,775)$(269,327)$172,560 
Vesting of restricted stock units3,333 — — — — — 
Stock-based compensation24,836 — 3,252 — — 3,252 
Unrealized loss on investments— — — (511)— (511)
Net loss— — — — (22,930)(22,930)
BALANCE - June 30, 202236,315,737 $5 $446,909 $(2,286)$(292,257)$152,371 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
9

Table of Contents
Black Diamond Therapeutics, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(Amounts in thousands, except share and per share amounts)
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
Black Diamond Therapeutics, Inc. (the “Company”) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
On February 1, 2021, the Company filed a shelf registration statement on Form S-3 ASR (the “Shelf”), with the Securities and Exchange Commission (the “SEC”), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an Open Market Sale AgreementSM with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies as its sales agent (the “ATM Program”). The Shelf became automatically effective upon filing on February 1, 2021. As of June 30, 2022, no sales have been made pursuant to the ATM Program.
The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred and common stock. The Company expects to continue to generate operating losses for the foreseeable future.
As of August 9, 2022, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.
The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.
10

Table of Contents
The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.
The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company’s business, including how it has impacted and may continue to impact the Company’s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment’s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company’s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company’s third party service providers have also experienced shutdowns or other business disruptions.
The extent to which COVID-19 ultimately impacts the Company’s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company’s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if the Company or any of the third parties with whom it engages were to experience prolonged business shutdowns or other disruptions, the Company’s ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on the Company’s business, results of operations and financial condition. The estimates of the impact on the Company’s business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
11

Table of Contents
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.
Recently issued accounting pronouncements
The Company believes that no recently issued accounting standards will have a material impact on its condensed consolidated financial statements, or apply to its operations.
3. FAIR VALUE MEASUREMENTS
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at June 30, 2022 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$53,761 $ $ $53,761 
Investments:
Commercial paper 14,542  14,542 
Corporate bonds 51,487  51,487 
U.S. Government agencies 38,984  38,984 
Total$53,761 $105,013 $ $158,774 
12

Table of Contents

Fair value measurements at December 31, 2021 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$63,730 $ $ $63,730 
Investments:
Corporate bonds 104,066  104,066 
U.S. Government agencies 39,921  39,921 
Total$63,730 $143,987 $ $207,717 
When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument.
There were no transfers in or out of Level 3 categories in the periods presented.
4. INVESTMENTS
As of June 30, 2022, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$14,547 $ $(5)$14,542 
Corporate bonds52,620  (1,133)51,487 
U.S. Government agencies40,132  (1,148)38,984 
Total$107,299 $ $(2,286)$105,013 
As of December 31, 2021, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Corporate bonds$104,261 $47 $(242)$104,066 
U.S. Government agencies40,140  (219)39,921 
Total$144,401 $47 $(461)$143,987 
As of June 30, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $47,880 that had maturities of one to three years.
As of December 31, 2021, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies and corporate bonds with a fair value of $86,187 that had maturities of one to three years.

13

Table of Contents
As of June 30, 2022, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $47,880, that had maturities of one to three years. As of December 31, 2021, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies and corporate bonds, with a fair value of $86,187, that had maturities of one to three years.
As of June 30, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. In determining whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. There have been no impairments of the Company’s assets measured and carried at fair value during the six months ended June 30, 2022 and the year ended December 31, 2021.
5. PROPERTY AND EQUIPMENT
Property and equipment, net consisted of the following:

June 30,
2022

December 31,
2021
Laboratory equipment$807 $682 
Furniture and fixtures17 17 
Computer and office equipment120 120 
Leasehold improvements2,512 2,437 
Construction in process 148 
Property and equipment3,456 3,404 
Less: accumulated depreciation(583)(369)
Total Property and Equipment, net$2,873 $3,035 

Depreciation expense for the six months ended June 30, 2022 and 2021 was $253 and $39, respectively.
6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following:

June 30,
2022

December 31,
2021
Contracted research services$11,072 $12,192 
Payroll and related expenses3,352 5,088 
Professional and consulting fees971 1,935 
Current portion of operating lease liability2,089 320 
Total accrued expenses and other current liabilities$17,484 $19,535 


14

Table of Contents
7. STOCK-BASED COMPENSATION
2020 Stock Option and Incentive Plan
The 2020 Stock Option and Incentive Plan (the “2020 Plan”) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (“IPO”) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2022, 1,449,384 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2021, were added to the 2020 Plan.
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2022.
Stock-based compensation expense
The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,
Six Months Ended
June 30,

2022202120222021
Stock options$3,000 $4,216 $6,193 $7,010 
Restricted stock units189 290 310 560 
Employee Stock Purchase Plan and Other63 52 124 82 

$3,252 $4,558 $6,627 $7,652 
For the six months ended June 30, 2022, the Company issued 37,874 shares of common stock out of its 2020 Plan under its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,
Six Months Ended
June 30,

2022

202120222021
Research and development$1,526 

$2,234 $3,054 $3,854 
General and administrative1,726 

2,324 3,573 3,798 

$3,252 

$4,558 $6,627 $7,652 
15

Table of Contents
Options
The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20214,903,839 $17.38 7.6$847 
Granted1,816,650 $3.33 
Exercised(3,565)$3.20 
Cancelled or forfeited(691,330)$16.50 
Outstanding June 30, 20226,025,594 $13.25 8.0$289 
Options vested or expected to vest at June 30, 20226,025,594 $13.25 8.0$289 
Options exercisable at June 30, 20222,478,157 $16.05 6.9$45 
For the six months ended June 30, 2022, total unrecognized compensation cost related to the unvested stock-options was $23,832, which is expected to be recognized over a weighted average period of 2.2 years.
Restricted stock units
The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2022:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 202130,667 $29.53 
Granted185,795 $2.32 
Vested(8,333)$29.24 
Unvested restricted common stock as of June 30, 2022208,129 $5.25 
The total fair value of time-based restricted stock units vested during the six months ended June 30, 2022 was $244.
For the six months ended June 30, 2022, total unrecognized compensation cost related to the time-based unvested restricted stock units was $757, which is expected to be recognized over a weighted average period of 1.3 years.
For the three months ended June 30, 2022, the Company granted to its employees 55,125 performance restricted stock units related to the achievement of certain clinical development and/or financing milestones. As of June 30, 2022, the Company had 267,125 performance restricted stock units outstanding.
Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.
16

Table of Contents
As of June 30, 2022, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the six months ended June 30, 2022.
Employee stock purchase plan
The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.
During the six months ended June 30, 2022 and 2021, there were 31,341 and no shares, respectively, issued under the 2020 ESPP.
8. NET LOSS PER SHARE
Net loss per share
The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):

Three Months Ended
June 30,
Six Months Ended
June 30,

2022

202120222021
Net loss$(22,930)

$(34,351)$(48,437)$(64,652)
Weighted average common shares outstanding, basic and diluted36,293,856 

36,182,541 36,282,636 36,152,942 
Net loss per share, basic and diluted$(0.63)

$(0.95)$(1.33)$(1.79)

The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Six Months Ended
June 30,

20222021
Options to purchase common stock6,025,594 5,209,744 
Unvested restricted stock208,129 51,007 
Shares issuable under employee stock purchase plan27,572 2,940 
Warrants to purchase common stock10,757 10,757 

6,272,052 5,274,448 
17

Table of Contents
9. LEASES
The Company has historically entered into lease arrangements for its facilities. As of June 30, 2022, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options.
Operating leases
In July 2020, the Company entered into a seven-year agreement with an option to extend for five additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease.
The Company previously leased an office space in Cambridge, MA under a lease that commenced in February 2019 for approximately 2,357 square feet of office space, which was set to expire on April 30, 2022, subject to an option to extend the lease for three additional years. Effective June 15, 2021, the lease was terminated, and the remaining right-of-use asset and lease liability were derecognized. A gain of $5 was recognized for the termination of the lease.
In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for five additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2022 and 2021:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Lease Cost
Operating lease cost$1,057 $613 $2,116 $1,075 
Short-term lease cost21 288 40 575 
Variable lease cost219 43 476 76 
Total lease cost$1,297 $944 $2,632 $1,726 
Other Operating Lease InformationJune 30, 2022June 30, 2021
Cash paid for amounts included in the measurement of lease liability$1,290 $732 
Weighted-average remaining lease term8.37.1
Weighted-average discount rate5.3 %5.3 %
The variable lease costs for the three and six months ended June 30, 2022 and 2021 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
18

Table of Contents
Future minimum lease payments under the Company’s operating leases as of June 30, 2022 were as follows:
As of June 30, 2022
2022 (excluding the six months ended June 30, 2022)
$1,460 
20234,244 
20244,359 
20254,477 
20264,599 
Thereafter16,973 
Total lease payments36,112 
Less: interest(7,266)
Total lease liability$28,846 

10. COMMITMENTS AND CONTINGENCIES
The Company enters into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.
License agreements
The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2022, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2022 or December 31, 2021.
Legal proceedings
The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
19

Table of Contents
11. BENEFIT PLANS
The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the “401(k) Plan”). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). All matching contributions are fully vested when made. During the three and six months ended June 30, 2022 and 2021, the Company contributed $199, $757, $220 and $565, respectively, to the 401(k) Plan.
20

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2021, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 17, 2022. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in our Annual Report on Form 10-K and in other SEC filings.
Overview
We are a clinical-stage precision oncology medicine company pioneering the discovery and development of MasterKey therapies. We target undrugged oncogenic driver mutations in patients with genetically defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology, or MAP, drug discovery engine, is designed to allow us to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Our goal is to identify families of mutations that can be inhibited with MasterKey therapies thereby providing precision oncology to greater numbers of patients with genetically defined tumors.
We have designed our product candidates to potently and selectively inhibit families of oncogenic mutations which occur across a range of tumor types. BDTX-1535, currently in the dose escalation portion of the ongoing Phase I clinical trial, was designed to inhibit oncogenic mutations in the ErbB-1 epidermal growth factor receptor (EGFR), while sparing normal, or wild type, EGFR (WT-EGFR) activity. The brain penetration properties of BDTX-1535 support the potential treatment of glioblastoma (GBM) and non-small cell lung cancer (NSCLC) patients with or without brain disease. BDTX-4933, currently in IND-enabling studies, was designed to inhibit Class I, II and III canonical and non-canonical mutations. In addition to being a highly selective and potent inhibitor, BDTX-4933 avoids paradoxical activation and is brain penetrant for the treatment of patients with or without brain disease. We are also leveraging our MAP drug discovery engine to identify other families of oncogenic mutations in validated oncogenes, which has the potential to expand the reach of MasterKey therapies. In April 2022, we announced the discontinuation of the development of BDTX-189 to focus on progressing our pipeline through important upcoming milestones for BDTX-1535 and BDTX-4933 as well as discovery efforts.
Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights while conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.
To date, we have funded our operations with proceeds from the sale of preferred stock and common stock. Since inception, we have incurred significant operating losses. Our net losses were $48.4 million and $64.7 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, we had an accumulated deficit of $292.3 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:
21

Table of Contents
advance clinical studies for BDTX-1535 and continue preclinical studies for BDTX-4933 and our other product candidates;
continue to identify additional product candidates from our proprietary MAP drug discovery engine;
obtain, maintain, expand and protect our intellectual property portfolio;
attract and retain key clinical, scientific, management and commercial personnel;
seek marketing approvals for our product candidates that successfully complete clinical trials, if any; and
acquire or in-license additional product candidates.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As of June 30, 2022, we had cash, cash equivalents and investments of approximately $160.9 million, which we believe will fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “—Liquidity and capital resources.” To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives.
COVID-19 considerations
The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.
The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company’s business, including how it has impacted and may continue to impact the Company’s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment’s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company’s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company’s third party service providers have also experienced shutdowns or other business disruptions.
The extent to which COVID-19 ultimately impacts the Company’s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts,
22

Table of Contents
developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company’s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if the Company or any of the third parties with whom it engages were to experience prolonged business shutdowns or other disruptions, the Company’s ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on the Company’s business, results of operations and financial condition. The estimates of the impact on the Company’s business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.
Additionally, inflation generally affects the Company by increasing its employee-related costs and clinical trial expenses, as well as other operating expenses. The Company’s financial condition and results of operations may also be impacted by other factors it may not be able to control, such as global supply chain disruptions, global trade disputes or political instability.
Components of our results of operations
Revenue
To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.
Operating expenses
Research and development expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:
expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval;
expenses incurred under agreements with contract research organizations, or CROs, that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and contract manufacturing organizations, or CMOs, that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs;
other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;
payments made in cash or equity securities under third-party licensing, acquisition and option agreements;
employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
costs related to compliance with regulatory requirements; and
allocated facilities-related costs, depreciation and other expenses, which include rent and utilities.
23

Table of Contents
We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Any nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.
Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under license, acquisition and option agreements. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program.
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our clinical trials for BDTX-1535, as well as conduct other preclinical and clinical development, including submitting regulatory filings for other product candidates.
We expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above historical levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.
At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following:
the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;
establishing an appropriate safety and efficacy profile with IND-enabling studies;
successful patient enrollment in and the initiation and completion of clinical trials;
the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration, or the FDA, and non-U.S. regulators;
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;
development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;
obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
24

Table of Contents
significant and changing government regulation;
launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and
maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.
Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.
General and administrative expenses
General and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, business development, finance, human resources, legal, information technology, pre-commercial and support personnel functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates and prepare for potential commercialization activities. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate.
Other income (expense)
Other income (expense) consists primarily of interest income earned on our cash equivalents and investment balances, and realized and unrealized foreign currency transaction gains and losses.
25

Table of Contents
Results of operations
Comparison of the three months ended June 30, 2022 and 2021
The following table summarizes our results of operations for the three months ended June 30, 2022 and 2021:

Three Months Ended
June 30,



2022

2021

Change

(in thousands)
Operating expenses:
Research and development$16,195 $26,719 $(10,524)
General and administrative6,978 7,996 (1,018)
Total operating expenses23,173 34,715 (11,542)
Loss from operations(23,173)(34,715)11,542 
Other income (expense):
Interest income386 948 (562)
Other (expense) income(143)(584)441 
Total other income (expense), net243 364 (121)
Net loss$(22,930)$(34,351)$11,421 
Research and development
Research and development expenses were $16.2 million for the three months ended June 30, 2022, compared to $26.7 million for the three months ended June 30, 2021. The following table summarizes our research and development expenses for the three months ended June 30, 2022 and 2021:

Three Months Ended
June 30,



2022

2021

Change

(in thousands)
BDTX-189 research and development expenses$2,561 $7,369 $(4,808)
BDTX-1535 research and development expenses1,089 1,822 (733)
Other research programs and platform development expenses5,189 9,334 (4,145)
Personnel expenses5,968 7,122 (1,154)
Allocated facility expenses974 840 134 
Other expenses414 232 182 
$16,195 $26,719 $(10,524)
The decrease of $10.5 million for the three months ended June 30, 2022 was primarily due to a decrease of $4.8 million in spend relating to BDTX-189 associated with reduced trial activities stemming from the discontinuation of the development of BDTX-189 to focus on upcoming milestones for our pipeline programs, BDTX-1535 and BDTX-4933. In addition, we decreased spend relating to other research programs and platform development by $4.1 million for the three months ended June 30, 2022 due to reduced spending on early discovery projects, compared to the three months ended June 30, 2021.
26

Table of Contents
General and administrative
General and administrative expenses were $7.0 million for the three months ended June 30, 2022 compared to $8.0 million for the three months ended June 30, 2021. This was primarily a result of flat personnel-related costs and a decrease in legal and other professional fees.
Other income (expense)
Other income was $0.2 million for the three months ended June 30, 2022, compared to $0.4 million for the three months ended June 30, 2021. The decrease was primarily attributable to amortization of premium on investments decreasing at a higher rate in 2022 compared to 2021 and interest income decreasing due to market conditions.
Comparison of the six months ended June 30, 2022 and 2021
The following table summarizes our results of operations for the six months ended June 30, 2022 and 2021:

Six Months Ended
June 30,



2022

2021

Change

(in thousands)
Operating expenses:
Research and development$33,981 $49,539 $(15,558)
General and administrative14,871 15,889 (1,018)
Total operating expenses48,852 65,428 (16,576)
Loss from operations(48,852)(65,428)16,576 
Other income (expense):
Interest income792 2,100 (1,308)
Other (expense) income(377)(1,324)947 
Total other income (expense), net415 776 (361)
Net loss$(48,437)$(64,652)$16,215 
Research and development
Research and development expenses were $34.0 million for the six months ended June 30, 2022, compared to $49.5 million for the six months ended June 30, 2021. The following table summarizes our research and development expenses for the six months ended June 30, 2022 and 2021:

Six Months Ended
June 30,



2022

2021

Change

(in thousands)
BDTX-189 research and development expenses$5,044 $15,487 $(10,443)
BDTX-1535 research and development expenses2,477 2,447 30 
Other research programs and platform development expenses10,722 17,229 (6,507)
Personnel expenses12,905 12,710 195 
Allocated facility expenses2,005 1,348 657 
Other expenses828 318 510 
$33,981 $49,539 $(15,558)
27

Table of Contents
The decrease of $15.6 million in the six months ended June 30, 2022 was primarily due to a decrease of $10.4 million in spend relating to BDTX-189 associated with reduced trial activities stemming from the discontinuation of the development of BDTX-189 to focus on upcoming milestones for our pipeline programs, BDTX-1535 and BDTX-4933. In addition, we decreased spend relating to other research programs and platform development by $6.5 million for the six months ended June 30, 2022 due to reduced spending on early discovery projects, compared to the six months ended June 30, 2021. Facility costs increased $0.7 million for the six months ended June 30, 2022, compared to the six months ended June 30, 2021 due to the signing of a new lease.
General and administrative
General and administrative expenses were $14.9 million for the six months ended June 30, 2022, compared to $15.9 million for the six months ended June 30, 2021. This was primarily a result of flat personnel-related costs and a decrease in legal and other professional fees.
Other income (expense)
Other income was $0.4 million for the six months ended June 30, 2022, compared to $0.8 million for the six months ended June 30, 2021. The decrease was primarily attributable to amortization of premium on investments decreasing at a higher rate in 2022 compared to 2021 and interest income decreasing due to market conditions.
Liquidity and capital resources
Sources of liquidity
Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of preferred stock. On February 3, 2020, we completed an IPO of 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231.3 million. We received $212.1 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. Through June 30, 2022, we had received net cash proceeds of $200.6 million from previous sales of our preferred stock and as of June 30, 2022, we had cash, cash equivalents and investments of $160.9 million.
Cash flows
The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):

Six Months Ended
June 30,

2022

2021
Cash used in operating activities$(46,667)

$(49,620)
Cash provided by investing activities
36,537 

51,674 
Cash provided by financing activities
153 

665 
Net (decrease) increase in cash and cash equivalents
$(9,977)

$2,719 
Operating activities
During the six months ended June 30, 2022, we used cash in operating activities of $46.7 million, primarily resulting from our net loss of $48.4 million, partially offset by the non-cash charge related to stock compensation expense of $6.6 million.
28

Table of Contents
During the six months ended June 30, 2021, we used cash in operating activities of $49.6 million, primarily resulting from our net loss of $64.7 million, partially offset by the non-cash charge related to stock compensation expense of $7.7 million and an increase in prepaid expenses and other current assets.
Changes in accounts payable and accrued expenses in all periods were generally due to growth in our business, the advancement of our product candidates, and the timing of vendor invoicing and payments.
Investing activities
During the six months ended June 30, 2022, we had cash provided by investing activities of $36.5 million primarily from the sales and maturities of investments.
During the six months ended June 30, 2021, we had cash provided by investing activities of $51.7 million primarily from the sales and maturities of investments.
Financing activities
During the six months ended June 30, 2022, we had cash provided by financing activities of $0.2 million, consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan.
During the six months ended June 30, 2021, we had cash provided by financing activities of $0.7 million consisting of proceeds from exercise of stock options.
Funding requirements
We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:
advance BDTX-1535 through clinical trials and continue preclinical studies for BDTX-4933;
advance preclinical development of our early stage programs, including our FGFR program, including plans for nominating a development candidate;
manufacture, or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late state and commercial manufacturing;
seek regulatory approvals for any product candidates that successfully complete clinical trials;
establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;
hire additional clinical, quality control and scientific personnel; and
obtain, maintain, expand and protect our intellectual property portfolio.
As of June 30, 2022, we had cash, cash equivalents and investments of $160.9 million, which we believe will fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.
Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:
29

Table of Contents
the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;
the costs, timing and outcome of regulatory review of our product candidates;
the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials;
the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
the costs of manufacturing commercial-grade product and necessary inventory to support commercial launch;
the ability to receive additional non-dilutive funding;
the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;
the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;
our ability to establish and maintain collaborations on favorable terms, if at all; and
the extent to which we acquire or in-license other product candidates and technologies.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in fixed payment obligations.
If we raise additional funds through collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Contractual obligations and commitments
The following summarizes our contractual obligations as of June 30, 2022:

Payments Due by Period

Less than 1 Year1 to 3 Years3 to 5 YearsMore than 5 Years

Total
(in thousands)
Property leases - commenced
$3,562 $8,718 $9,199 $14,633 $36,112 
Total
$3,562 $8,718 $9,199 $14,633 

$36,112 
30

Table of Contents
Property leases – commenced
The amounts reported for property leases represent future minimum lease payments under non-cancelable operating leases in effect as of June 30, 2022. The minimum lease payments do not include common area maintenance charges or real estate taxes.
Other contractual obligations
The contractual obligations table does not include any potential future milestone p